Abacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infection

Cruciani, Mario; Martí‐Carvajal, Arturo J; Mengoli, Carlo; Serpelloni, Giovanni; Bovo, Chiara; Moyle, Graeme

doi:10.1002/14651858.cd009390.pub2

Cited by 3 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, some phytochemicals have been investigated as potent inhibitors of COVID-19 main protease. Some of these phytochemicals include kaempferol (14), quercetin (15), luteolin-7-glucoside ( 16), demethoxycurcumin (17), naringenin (18), apigenin-7-glucoside (19), oleuropein (20), curcumin (21), catechin (22), epigallocatechingallate (23), zingerol (24), gingerol (25), allicin (26) and lycorine (27) (Fig. 2 The anti-infective activities (antiviral and antimicrobial) of 3,5-dicaffeoylquinic acid (29), acteoside or verbascoside (30) and kampferol-7-O-glucoside (31) had also been reported in literature (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…Antiviral compounds are grouped into classes such as: protease inhibitors, integrase inhibitors, nucleoside analogues, fusion inhibitors, neuraminidase inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors etc [18]. A nucleoside reverse transcriptase inhibitor (NRTI) e.g Abacavir (2) and Didanosine (3), acts by inhibiting viral DNA elongation, replication and synthesis [19]. Emtricitabine acts by inhibiting the transcription of viral RNA into DNA, and therefore preventing the virus from incorporating its DNA into host DNA [20,21].…”

Section: Classes Of Antiviral Agents and Their Mechanism Of Actionmentioning

confidence: 99%

See 1 more Smart Citation

Potentials of Medicinal Plants with Antiviral Properties: The Need for a Paradigm Shift in Developing Novel Antivirals Against COVID-19

Oladosu

Moses

Adigwe

et al. 2021

JAMMR

View full text Add to dashboard Cite

The menace of COVID-19 continues to ravage the world despite deployment of vaccines, and the development of oral antiviral pills whose effectiveness are still being evaluated. As the problems persist, Scientists are continuously searching for new resources and re-evaluating old ones that be used to effectively contain the pandemic. A search through literature has shown a huge amount of scientific resources in medicinal plant research which could be leverage. Many medicinal plants have been demonstrated to possess various antiviral activities against influenza virus, SARS-CoV, herpes simplex virus, vesicular stomatitis virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, simian immunodeficiency virus, echovirus, adenovirus, Newcastle disease virus, duck plague virus, measles virus, polio viruses, yellow fever viruses, Sindbis virus, human cytomegalovirus, Rift valley fever virus, feline herpesvirus, lumpy skin disease virus, and canine distemper virus. Medicinal plants are known to be a reservoir of bioactive compounds with useful pharmacological actives. This revision has identified one hundred and twelve (112) plants found with various antiviral activities. These plants cut across different families. An intriguing observation is the reported presence of antiviral in different classes of phytochemicals like alkaloids, flavonoids, tannins, anthraquinones, glucosides, polyphenols, saponins, essential oils, peptides and polysaccharides. There is the need for concerted paradigm shift to natural products of plant origin towards developing novel antiviral agents against COVID-19 especially with the reported safety challenge of adverse events and serious adverse events associated with already developed vaccines and pills.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Classes Of Antiviral Agents and Their Mechanism Of Actionmentioning

confidence: 99%

Potentials of Medicinal Plants with Antiviral Properties: The Need for a Paradigm Shift in Developing Novel Antivirals Against COVID-19

Oladosu

Moses

Adigwe

et al. 2021

JAMMR

View full text Add to dashboard Cite

show abstract

“…3,4 Medical improvements and increased access to HIV treatment, such as combination antiretroviral therapy (ART), have led to a shift from a highly fatal to a treatable and controllable disease. [5][6][7][8][9] With the improvement in lifespan, PLHIV faces increasing morbidity and mortality from non-communicable diseases (NCD) like diabetes mellitus and cardiovascular disease. 10 This double burden of HIV and chronic comorbidity is particularly challenging for resource-limited countries, such as Ethiopia, with already constrained health care systems.…”

Section: Introductionmentioning

confidence: 99%

Development of Hypertension and Diabetes Mellitus, and Associated Factors, Among Adult HIV Patients in Ethiopia

Tegene¹,

Mengesha²,

Putman³

et al. 2023

HIV

View full text Add to dashboard Cite

Medical improvements and increased access to treatment have turned HIV from a highly fatal disease into a treatable and controllable disease. With the improvement in lifespan, HIV patients face increasing morbidity and mortality from chronic comorbidities (hypertension and diabetes mellitus). There is, nevertheless, a paucity of information on the scale of HIV noncommunicable disease comorbidity and its associated factors. This study aimed to investigate the incidence and predictors of chronic comorbidity in HIV patients in a resource-limited setting. Methods: A prospective cohort study was conducted from 2019 to 2021. We included 520 HIV patients at baseline. Patients without hypertension or diabetes were followed for two years to determine the incidence of developing comorbidities. Nine trained nurses used a pre-tested structured questionnaire to collect data during routine care consultations in three hospitals in southern Ethiopia. To find predictors of these chronic comorbidities, a multivariable logistic regression analysis was used. Results: After two years, 54 out of 377 participants, or 14%, had chronic comorbidity, which is defined as having diabetes and/or hypertension. Hypertension (12%) and diabetes (4%), respectively, were observed. When compared to those who were not overweight, the risk of developing chronic comorbidity was three times higher in overweight people [AOR = 3.45, 95% CI: (1.04, 11.45), P = 0.045]. Older participants were about 6 times more likely than younger participants to have chronic comorbidity [AOR = 4.93, 95% CI: (1.56, 15.57), P = 0.007]. Those who did not engage in regular physical activity were twice as likely to develop chronic comorbidity [AOR = 2.16, 95% CI: (1.09, 4.29), P = 0.027]. Conclusion:The incidence of chronic comorbidity was high in the study population. Targeted screening for early signs of chronic comorbidity, nutritional counseling, and awareness creation in regular physical activity programs should be integrated into HIV care to prevent and control chronic comorbidity in resource-limited settings.

show abstract

A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2

Kim

Yoo

et al. 2021

Microorganisms

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in serious chaos all over the world. In addition to the available vaccines, the development of treatments to cure COVID-19 should be done quickly. One of the fastest strategies is to use a drug-repurposing approach. To provide COVID-19 patients with useful information about medicines currently being used in clinical trials, twenty-four compounds, including antiviral agents, were selected and assayed. These compounds were applied to verify the inhibitory activity for the protein function of 3CLpros (main proteases) of SARS-CoV and SARS-CoV-2. Among them, viral reverse-transcriptase inhibitors abacavir and tenofovir revealed a good inhibitory effect on both 3CLpros. Intriguingly, sildenafil, a cGMP-specific phosphodiesterase type 5 inhibitor also showed significant inhibitory function against them. The in silico docking study suggests that the active-site residues located in the S1 and S2 sites play key roles in the interactions with the inhibitors. The result indicates that 3CLpros are promising targets to cope with SAR-CoV-2 and its variants. The information can be helpful to design treatments to cure patients with COVID-19.

show abstract

Abacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infection

Cited by 3 publications

References 34 publications

Potentials of Medicinal Plants with Antiviral Properties: The Need for a Paradigm Shift in Developing Novel Antivirals Against COVID-19

Potentials of Medicinal Plants with Antiviral Properties: The Need for a Paradigm Shift in Developing Novel Antivirals Against COVID-19

Development of Hypertension and Diabetes Mellitus, and Associated Factors, Among Adult HIV Patients in Ethiopia

A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2

Contact Info

Product

Resources

About